Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IDEAYA Biosciences (IDYA) EBT Margin (2020 - 2025)

IDEAYA Biosciences (IDYA) has disclosed EBT Margin for 6 consecutive years, with 869.53% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 118959.0% to 869.53% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 72.84% through Dec 2025, up 459823.0% year-over-year, with the annual reading at 72.84% for FY2025, 459823.0% up from the prior year.
  • EBT Margin hit 869.53% in Q4 2025 for IDEAYA Biosciences, down from 52.18% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 52.18% in Q3 2025 to a low of 2059.11% in Q4 2024.
  • Historically, EBT Margin has averaged 519.11% across 5 years, with a median of 384.53% in 2022.
  • Biggest five-year swings in EBT Margin: tumbled -99035bps in 2024 and later skyrocketed 118959bps in 2025.
  • Year by year, EBT Margin stood at 620.16% in 2021, then fell by -6bps to 657.46% in 2022, then plummeted by -63bps to 1068.77% in 2023, then tumbled by -93bps to 2059.11% in 2024, then surged by 58bps to 869.53% in 2025.
  • Business Quant data shows EBT Margin for IDYA at 869.53% in Q4 2025, 52.18% in Q3 2025, and 2059.11% in Q4 2024.